These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 6539428)

  • 1. Biochemical and behavioral evaluation of pergolide as a dopamine agonist in the rat brain.
    Jiang DH; Reches A; Wagner HR; Fahn S
    Neuropharmacology; 1984 Mar; 23(3):295-301. PubMed ID: 6539428
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparison of the potencies of various dopamine receptor agonists in models for pre- and postsynaptic receptor activity.
    Feenstra MG; Sumners C; Goedemoed JH; de Vries JB; Rollema H; Horn AS
    Naunyn Schmiedebergs Arch Pharmacol; 1983 Sep; 324(2):108-15. PubMed ID: 6646238
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stimulation of pre- and postsynaptic dopamine receptors by an ergoline and by partial ergoline.
    Rabey JM; Passeltiner P; Markey K; Asano T; Goldstein M
    Brain Res; 1981 Nov; 225(2):347-56. PubMed ID: 6118195
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Altered behavioral response to a D2 agonist, LY141865, in spontaneously hypertensive rats exhibiting biochemical and endocrine responses similar to those in normotensive rats.
    Fuller RW; Hemrick-Luecke SK; Wong DT; Pearson D; Threlkeld PG; Hynes MD
    J Pharmacol Exp Ther; 1983 Nov; 227(2):354-9. PubMed ID: 6138425
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relative selectivity of 6,7-dihydroxy-2-dimethylaminotetralin, N-n-propyl-3-(3-hydroxyphenyl)piperidine, N-n-propylnorapomorphine and pergolide as agonists at striatal dopamine autoreceptors and postsynaptic dopamine receptors.
    Claustre Y; Fage D; Zivkovic B; Scatton B
    J Pharmacol Exp Ther; 1985 Feb; 232(2):519-25. PubMed ID: 2857197
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Behavioural stimulation is induced by separate dopamine D-1 and D-2 receptor sites in reserpine-pretreated but not in normal rats.
    Arnt J
    Eur J Pharmacol; 1985 Jul; 113(1):79-88. PubMed ID: 2931283
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Degree of selectivity of pergolide as an agonist at presynaptic versus postsynaptic dopamine receptors: implications for prevention or treatment of tardive dyskinesia.
    Fuller RW; Clemens JA; Hynes MD
    J Clin Psychopharmacol; 1982 Dec; 2(6):371-5. PubMed ID: 7174859
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of the partial dopamine receptor agonists SDZ 208-911, SDZ 208-912 and terguride on central monoamine receptors. A behavioral, biochemical and electrophysiological study.
    Svensson K; Ekman A; Piercey MF; Hoffmann WE; Lum JT; Carlsson A
    Naunyn Schmiedebergs Arch Pharmacol; 1991 Sep; 344(3):263-74. PubMed ID: 1683686
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Central dopamine receptors mediating pergolide-induced elevation of serum corticosterone in rats. Characterization by the use of antagonists.
    Fuller RW; Snoddy HD
    Neuropharmacology; 1984 Dec; 23(12A):1389-94. PubMed ID: 6527743
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protective effects of pergolide on dopamine levels in the 6-hydroxydopamine-lesioned mouse brain.
    Asanuma M; Ogawa N; Nishibayashi S; Kawai M; Kondo Y; Iwata E
    Arch Int Pharmacodyn Ther; 1995; 329(2):221-30. PubMed ID: 8540762
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Behavioural and biochemical alterations in the function of dopamine receptors following repeated administration of L-DOPA to rats.
    Hall MD; Cooper DR; Fleminger S; Rupniak NM; Jenner P; Marsden CD
    Neuropharmacology; 1984 May; 23(5):545-53. PubMed ID: 6539859
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Repeated administration of pergolide to rats attenuates the acute elevation of serum corticosterone by pergolide.
    Fuller RW; Snoddy HD
    Pharmacol Biochem Behav; 1981 Dec; 15(6):933-6. PubMed ID: 7323119
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pergolide potentiates L-DOPA-induced dopamine release in rat striatum after lesioning with 6-hydroxydopamine.
    Dethy S; Laute MA; Damhaut P; Goldman S
    J Neural Transm (Vienna); 1999; 106(2):145-58. PubMed ID: 10226935
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological profile of dopamine receptor agonists as studied by brain dialysis in behaving rats.
    Imperato A; Tanda G; Frau R; Di Chiara G
    J Pharmacol Exp Ther; 1988 Apr; 245(1):257-64. PubMed ID: 3258912
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Microdialysis study of tolcapone effect during blockage of neuronal dopamine reuptake caused by GBR-12909].
    Budygin EA; Gaĭnetdinov RR; Raevskiĭ KS; Li IH; Mannisto PT
    Eksp Klin Farmakol; 1997; 60(5):8-10. PubMed ID: 9483396
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of phencyclidine on dopamine synthesis and metabolic in rat striatum.
    Doherty JD; Simonovic M; So R; Meltzer HY
    Eur J Pharmacol; 1980 Jul; 65(2-3):139-49. PubMed ID: 7398783
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pergolide elevation of MHPG sulphate concentration in rat hypothalamus blocked by spiperone and mimicked by other dopamine agonists.
    Fuller RW; Hemrick-Luecke SK; Perry KW; Toomey RE
    J Pharm Pharmacol; 1985 Apr; 37(4):268-70. PubMed ID: 2860228
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molindone: higher doses needed to block pergolide-induced elevation of serum corticosterone than to elevate dopamine metabolites in brain.
    Fuller RW; Snoddy HD
    Life Sci; 1983 Dec; 33(23):2357-61. PubMed ID: 6645804
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Central antidopaminergic properties of 2-bromolisuride, an analogue of the ergot dopamine agonist lisuride.
    Wachtel H; Kehr W; Sauer G
    Life Sci; 1983 Dec; 33(26):2583-97. PubMed ID: 6607392
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elevation of serum corticosterone in rats by dopamine agonists related in structure to pergolide.
    Fuller RW; Snoddy HD; Mason NR; Clemens JA; Bemis KG
    Neuroendocrinology; 1983; 36(4):285-90. PubMed ID: 6866215
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.